

DGHO   
DEUTSCHE GESELLSCHAFT FÜR  
HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE

OeGHO  
Österreichische Gesellschaft für  
Hämatologie & Medizinische Onkologie

SSMO  
SSOM  
SGMO

SGKSSH

# JAHRESTAGUNG

Jahrestagung der Deutschen, Österreichischen  
und Schweizerischen Gesellschaften für  
Hämatologie und Medizinische Onkologie

[www.haematologie-onkologie-2017.com](http://www.haematologie-onkologie-2017.com)

2017

STUTTGART

29.9.-3.10.

***Neue Konzepte im HLA Matching***

**Katharina Fleischhauer**

Institut für Zelltherapeutische Forschung



*Universitätsklinikum Essen*

# Disclosure of conflicts of interest

## Other Financial Relationships

The research was partly supported by Genome Diagnostics B.V., Utrecht, The Netherlands



# Donor-Recipient HLA mismatches

---

## Non-Self reactive TCR

Alloreactive T cells

HLA-A,B,C,DR,DQ,DP

*GvHD and GvL*

## Missing-Self reactive KIR

Alloreactive NK cells

HLA-(A),B,C

*GvL*

# Donor-Recipient HLA mismatches

---

## Non-Self reactive TCR

Alloreactive T cells


HLA-A,B,C,DR,DQ,DP

*GvHD and GvL*

- **Haploidentical:**
  - ✓ Full Haplotype mismatch
- **Matched Unrelated Donors (MUD):**
  - ✓ 8/8 – 7/8

# Haploidentical Transplantation


- **No definitive HLA matching concepts**
  - ✓ Number of Matches on the unshared haplotype?
  - ✓ Non-Inherited Maternal Antigens (NIMA?)



Relapse remains a problem


# “Alternative Haplotype” for Relapse

Switch Second Donor



Imus et al., Biol Blood Marrow Transplant 2017

“HLA Loss” Immune Escape




Vago & Ciceri., Biol Blood Marrow Transplant 2017

# qPCR Chimerism for HLA loss relapse

## "HLA" host chimerism (%)

De novo developed  
HLA-A, -C, -DPB1



## "non-HLA" host chimerism (%)

Commercially available  
indels across the genome


Insertion




Deletion



## "Classical" relapse




## HLA loss relapse






# qPCR Chimerism for HLA loss relapse

Classical Relapse



HLA loss Relapse




10 Reactions (HLA-A,C,DPB1)

71.6% Informativity after Haplo

Ahci & Toffalori et al., Blood 2017

# MUD: Limited T cell alloreactivity




## Permissive Transplantation

- Cellular (T-depletion, Treg, ...)
- Pharmacological (CNI, PTCy, ...)
- Genetic (low T cell alloreactivity)

# T cell alloreactivity


Minor  
Antigens



Conventional recognition  
of polymorphic peptides


(also from mismatched HLA = PIRCHES)

Major HLA mismatches





Cross-recognition of mismatched HLA

# Naïve and Memory alloreactive T cells



# HLA mismatches in MUD-HSCT



# Permissive HLA Mismatches?

---

## Several 9/10 MUD:

Permissive mismatch combinations (e.g. C\*03:03 vs. 03:04)

*Fernandez-Vina et al., Blood 2014*

*Kawase et al. Blood 2011*

Predicted Indirectly ReCognized HLA Epitopes (PIRCHE)

*Thus et al., Biol Blood Marrow Transplant 2014*

## Several 10/10 MUD:

HLA-DPB1 permissive T Cell Epitope (TCE) mismatches

*Zino et al., Blood 2004*

*Fleischhauer et al., Lancet Oncol 2012*


*Pidala et al., Blood 2014*

High Expression single GvH mismatches


*Petersdorf et al., N Engl J Med 2015*

# Clinical Association of TCE Mismatches

## Overall Survival



## Relapse



Fleischhauer et al., Bone Marrow Transplant 2014  
 Crocchiolo et al., Blood 2009  
 Fleischhauer et al., Lancet Oncol 2012  
 Pidala et al., Blood 2014  
 Fleischhauer & Shaw Blood 2017

Matched vs. Permissive	Relapse	GvHD 3-4
HR	1.31	0.96
P	0.05	0.77

# Online Tools for TCE matching

## DPB1 T-Cell Epitope Algorithm



**IPD - IMGT/HLA**

Overview | IMGT/HLA | KIR | MHC | HPA | ESTDAB | Contact | Support

IPD > IMGT/HLA > DPB TCE Algorithm

### DPB1 T-Cell Epitope Algorithm

#### Prospective HLA-DPB1 Typing

Prospective Patient 1 <input type="text"/>	DPB1* 04:01 <input type="text"/>	DPB1* 04:02 <input type="text"/>
Prospective Donor 1 <input type="text"/>	DPB1* 04:01 <input type="text"/>	DPB1* 09:01 <input type="text"/>

[Add Further Donors.](#)

<http://www.ebi.ac.uk/ipd/imgt/hla/dpb.html>

Collaboration with SGH Marsh  
(Anthony Nolan, London)

**Details of DPB1 TCE3 Grading** [X] Close

Patient: 500011 Donor: DE-XYZ-4424634


DPB11	DPB12	DPB11	DPB12	Prob. [%]	DPB1 TCE3
03:01	03:01	02:01	03:01	66	P
06:01	03:01	02:01	03:01	16	P
09:01	03:01	02:01	03:01	10	G
03:01	03:01	02:01	104:01	2	P
06:01	09:01	02:01	03:01	1	G
06:01	06:01	02:01	03:01	1	P
03:01	03:01	02:01	124:01	1	P
06:01	03:01	02:01	104:01	1	P

First Previous 1 2 3 4 5 Next Last

TCE group: 25

Courtesy of CH Müller  
(ZKR D, Ulm)

# Prospective Study HLA-DPB1 TCE Matching



Essen

Hamburg

Dresden

Heidelberg

Mainz

...

# Conclusions

---

- Haplo-HSCT:
  - ✓ Relapse: test for HLA loss and switch to new donor at 2nd Tx
- MUD-HSCT:
  - ✓ “HLA–matched“ Sibling and MUD biologically different!
  - ✓ Permissive HLA-DP TCE mismatches preserved GvL but limited GvHD
  - ✓ Prospective TCE trial open [katharina.fleischhauer@uk-essen.de](mailto:katharina.fleischhauer@uk-essen.de)

# Acknowledgements

## Institute for Experimental Cellular Therapy

Pietro Crivello

Esteban Arrieta-Bolanos

Müberra Ahci

Thuja Meurer

Maximilian Metzging

Karin Stempelmann

## Institute for Transfusion Medicine

Anderas Heinold

Peter Horn

## Department of Stem Cell Transplantation

Hellmut Ottinger

Dietrich Beelen



## San Raffaele Scientific Institute Milan

Cristina Toffalori

Fabio Ciceri

Luca Vago

## Leiden University Medical Center

Michel Kester

Peter van Balen

Frederik Falkenburg

## Ruhr Universität Bochum

Dominik Megger

Barbara Sitek

## Funding Bodies

EU-Transcan    Jackstädt Stiftung

DKTK            DJCLS            GenDx